0.585
0.03 (5.41%)
| Previous Close | 0.555 |
| Open | 0.570 |
| Volume | 102,188 |
| Avg. Volume (3M) | 308,384 |
| Market Cap | 80,064,312 |
| Price / Book | 8.61 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,517.31% |
| Diluted EPS (TTM) | -0.030 |
| Current Ratio (MRQ) | 16.69 |
| Operating Cash Flow (TTM) | -2.79 M |
| Return on Assets (TTM) | -21.46% |
| Return on Equity (TTM) | -34.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (AU) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | CLEO DIAGN FPO [COV] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company’s first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 76.28% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |